.STUDY HIGHLIGHT.16 Oct 2024. In the NIAGARA hearing, the addition of perioperative durvalumab to basic treatment for muscle-invasive sac cancer cells boosted event-free as well as on the whole survival, denoting a brand new therapy possibility for this condition.